148 related articles for article (PubMed ID: 20407443)
21. A computational approach for investigating the mutational landscape of RAC-alpha serine/threonine-protein kinase (AKT1) and screening inhibitors against the oncogenic E17K mutation causing breast cancer.
Thirumal Kumar D; Jain N; Evangeline J; Kamaraj B; Siva R; Zayed H; George Priya Doss C
Comput Biol Med; 2019 Dec; 115():103513. PubMed ID: 31698236
[TBL] [Abstract][Full Text] [Related]
22. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
[TBL] [Abstract][Full Text] [Related]
23. The effect of LKB1 on the PI3K/Akt pathway activation in association with PTEN and PIK3CA in HNC.
Ekizoglu S; Dogan S; Ulker D; Seven D; Gozen ED; Karaman E; Buyru N
Clin Otolaryngol; 2015 Dec; 40(6):622-8. PubMed ID: 25850957
[TBL] [Abstract][Full Text] [Related]
24. A novel AKT3 mutation in melanoma tumours and cell lines.
Davies MA; Stemke-Hale K; Tellez C; Calderone TL; Deng W; Prieto VG; Lazar AJ; Gershenwald JE; Mills GB
Br J Cancer; 2008 Oct; 99(8):1265-8. PubMed ID: 18813315
[TBL] [Abstract][Full Text] [Related]
25. AKT1
Kircher DA; Trombetti KA; Silvis MR; Parkman GL; Fischer GM; Angel SN; Stehn CM; Strain SC; Grossmann AH; Duffy KL; Boucher KM; McMahon M; Davies MA; Mendoza MC; VanBrocklin MW; Holmen SL
Mol Cancer Res; 2019 Sep; 17(9):1787-1800. PubMed ID: 31138602
[TBL] [Abstract][Full Text] [Related]
26. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
Hafner C; Landthaler M; Vogt T
Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
[TBL] [Abstract][Full Text] [Related]
27. Absence of oncogenic AKT1 E17K mutation in prostate, esophageal, laryngeal and urothelial carcinomas, hepatoblastomas, gastrointestinal stromal tumors and malignant meningiomas.
Eom HS; Kim MS; Hur SY; Yoo NJ; Lee SH
Acta Oncol; 2009; 48(7):1084-5. PubMed ID: 19353338
[No Abstract] [Full Text] [Related]
28. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Dunlap J; Le C; Shukla A; Patterson J; Presnell A; Heinrich MC; Corless CL; Troxell ML
Breast Cancer Res Treat; 2010 Apr; 120(2):409-18. PubMed ID: 19418217
[TBL] [Abstract][Full Text] [Related]
29. Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components.
Mishima C; Kagara N; Ikeda JI; Morii E; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S
Am J Pathol; 2018 May; 188(5):1106-1112. PubMed ID: 29454754
[TBL] [Abstract][Full Text] [Related]
30. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
[TBL] [Abstract][Full Text] [Related]
31. PIK3CA mutations in mucinous cystic neoplasms of the pancreas.
Garcia-Carracedo D; Chen ZM; Qiu W; Huang AS; Tang SM; Hruban RH; Su GH
Pancreas; 2014 Mar; 43(2):245-9. PubMed ID: 24518503
[TBL] [Abstract][Full Text] [Related]
32. Absence of AKT1 mutations in glioblastoma.
Bleeker FE; Lamba S; Zanon C; van Tilborg AA; Leenstra S; Troost D; Hulsebos T; Vandertop WP; Bardelli A
PLoS One; 2009 May; 4(5):e5638. PubMed ID: 19461960
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells.
Guo G; Qiu X; Wang S; Chen Y; Rothman PB; Wang Z; Chen Y; Wang G; Chen JL
Oncogene; 2010 Jul; 29(26):3845-53. PubMed ID: 20440266
[TBL] [Abstract][Full Text] [Related]
34. PIK3R1 underexpression is an independent prognostic marker in breast cancer.
Cizkova M; Vacher S; Meseure D; Trassard M; Susini A; Mlcuchova D; Callens C; Rouleau E; Spyratos F; Lidereau R; Bièche I
BMC Cancer; 2013 Nov; 13():545. PubMed ID: 24229379
[TBL] [Abstract][Full Text] [Related]
35. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
Flatley E; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2013 Jul; 44(7):1320-7. PubMed ID: 23352210
[TBL] [Abstract][Full Text] [Related]
36. A new mutational AKTivation in the PI3K pathway.
Brugge J; Hung MC; Mills GB
Cancer Cell; 2007 Aug; 12(2):104-7. PubMed ID: 17692802
[TBL] [Abstract][Full Text] [Related]
37. Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network.
Pfarr N; Allgäuer M; Steiger K; Weichert W; Schirmacher P; Noske A; Stenzinger A
Pathology; 2019 Jun; 51(4):362-368. PubMed ID: 31010589
[TBL] [Abstract][Full Text] [Related]
38. AKT1
John P; Waldt N; Liebich J; Kesseler C; Schnabel S; Angenstein F; Sandalcioglu IE; Scherlach C; Sahm F; Kirches E; Mawrin C
Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12780. PubMed ID: 34837233
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
Cejalvo JM; Pérez-Fidalgo JA; Ribas G; Burgués O; Mongort C; Alonso E; Ibarrola-Villava M; Bermejo B; Martínez MT; Cervantes A; Lluch A
Breast Cancer Res Treat; 2016 Nov; 160(1):69-77. PubMed ID: 27628192
[TBL] [Abstract][Full Text] [Related]
40. Effects of AKT1 E17K mutation hotspots on the biological behavior of breast cancer cells.
Wu W; Chen Y; Huang L; Li W; Tao C; Shen H
Int J Clin Exp Pathol; 2020; 13(3):332-346. PubMed ID: 32269671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
